Happi Staff03.26.20
Amyris, Inc. is launching a hand sanitizer to help address the high demand triggered by COVID-19. The Emeryville, CA-based company says is leveraging its existing capabilities to fast track the availability Pipette Baby branded hand sanitizer that can be used by everyone, the company said.
"We are committed to No Compromise products, formulations and ingredients. Our hand sanitizer is a great example of swiftly applying our market-leading squalane moisturizer to an immediate need,” said John Melo, president and CEO of Amyris. “We expect to produce an estimated 30,000 units in the first weeks and to expand production quickly. First shipments are expected as early as next week.”
The product will be available to the public on PipetteBaby.com.
In other COVID-19 related company news, in partnership with the Infectious Diseases Research Institute (IDRI), Amyris has completed initial testing of its fermentation-derived squalene as a vaccine adjuvant. The company says it is in active discussion with a leader in the pharmaceutical industry to target broad application of Amyris squalene in flu and potential COVID-19 vaccines.
"We are committed to No Compromise products, formulations and ingredients. Our hand sanitizer is a great example of swiftly applying our market-leading squalane moisturizer to an immediate need,” said John Melo, president and CEO of Amyris. “We expect to produce an estimated 30,000 units in the first weeks and to expand production quickly. First shipments are expected as early as next week.”
The product will be available to the public on PipetteBaby.com.
In other COVID-19 related company news, in partnership with the Infectious Diseases Research Institute (IDRI), Amyris has completed initial testing of its fermentation-derived squalene as a vaccine adjuvant. The company says it is in active discussion with a leader in the pharmaceutical industry to target broad application of Amyris squalene in flu and potential COVID-19 vaccines.